URGN UroGen Pharma Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: URGN

Price (delayed)

$14.3

Market cap

$487.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.55

Enterprise value

$491.52M

Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, ...

Highlights
The gross profit rose by 29% year-on-year and by 8% since the previous quarter
The revenue has grown by 29% YoY and by 7% from the previous quarter
UroGen Pharma's equity has plunged by 55% from the previous quarter but it has increased by 27% YoY
The quick ratio has contracted by 21% from the previous quarter but it has grown by 3.6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.urogen.com
Peers: OMER OMGA

Key stats

What are the main financial stats of URGN
Market
Shares outstanding
34.12M
Market cap
$487.95M
Enterprise value
$491.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.94
Earnings
Revenue
$82.71M
EBIT
-$83.61M
EBITDA
-$81.9M
Free cash flow
-$76.57M
Per share
EPS
-$3.55
Free cash flow per share
-$2.66
Book value per share
-$2.11
Revenue per share
$2.87
TBVPS
$6.18
Balance sheet
Total assets
$178.31M
Total liabilities
$243.52M
Debt
$99.4M
Equity
-$65.21M
Working capital
$137.97M
Liquidity
Debt to equity
-1.52
Current ratio
5.42
Quick ratio
4.91
Net debt/EBITDA
-0.04
Margins
EBITDA margin
-99%
Gross margin
88.7%
Net margin
-123.6%
Operating margin
-79.2%
Efficiency
Return on assets
-70.5%
Return on equity
N/A
Return on invested capital
-56.2%
Return on capital employed
-56.8%
Return on sales
-101.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

URGN stock price

How has the UroGen Pharma stock price performed over time
Intraday
0.28%
1 week
1.06%
1 month
4.69%
1 year
11.72%
YTD
-4.67%
QTD
-4.67%

Financial performance

How have UroGen Pharma's revenue and profit performed over time
Revenue
$82.71M
Gross profit
$73.35M
Operating income
-$65.54M
Net income
-$102.24M
Gross margin
88.7%
Net margin
-123.6%
The operating margin is up by 36% year-on-year and by 14% since the previous quarter
The gross profit rose by 29% year-on-year and by 8% since the previous quarter
The revenue has grown by 29% YoY and by 7% from the previous quarter
URGN's net margin is up by 28% year-on-year and by 9% since the previous quarter

Growth

What is UroGen Pharma's growth rate over time

Valuation

What is UroGen Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
4.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.94
The company's EPS rose by 26% YoY and by 17% QoQ
UroGen Pharma's equity has plunged by 55% from the previous quarter but it has increased by 27% YoY
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 4787.2 but 13% higher than the last 4 quarters average of 4.4
The revenue has grown by 29% YoY and by 7% from the previous quarter

Efficiency

How efficient is UroGen Pharma business performance
The company's return on sales rose by 35% YoY and by 13% QoQ
URGN's return on invested capital is up by 24% year-on-year and by 6% since the previous quarter
The ROA has increased by 10% from the previous quarter and by 7% YoY

Dividends

What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for URGN.

Financial health

How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 27% lower than its total liabilities
UroGen Pharma's total assets has increased by 31% YoY but it has decreased by 8% QoQ
The current ratio is down by 23% since the previous quarter
UroGen Pharma's equity has plunged by 55% from the previous quarter but it has increased by 27% YoY
The debt to equity is down by 37% YoY but it is up by 36% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.